2-氯-N-环己烷-N-苯基乙胺 | 100721-33-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯-N-环己烷-N-苯基乙胺
• 中文别名: 2-氯-N-环己基-N-苯基乙酰胺
• 英文名称: 2-chloro-N-cyclohexyl-N-phenylacetamide
• 英文别名: chloro-acetic acid-(N-cyclohexyl-anilide)；Chlor-essigsaeure-(N-cyclohexyl-anilid)
• CAS: 100721-33-3
• 化学式: C₁₄H₁₈ClNO
• 分子量: 251.756
• InChiKey: WDAVIQBJLVXQGA-UHFFFAOYSA-N

物化性质

• 溶解度：
  36.6 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  2-氯-N-环己烷-N-苯基乙胺 在 potassium carbonate 、 三氟乙酸 作用下， 以 乙腈 为溶剂， 生成
  参考文献：
  名称：

  Higher-Affinity Agonists of 5-HT_1AR Discovered through Tuning the Binding-Site Flexibility

  摘要：

  Discovery of high-affinity and high-selectivity agonists of 5-HT1AR. has become very attractive due to their potential therapeutic effects on multiple 5-HT1AR-related psychological and neurological problems. On the basis of our previously designed lead compound FW01 (K-i = 51.9 nM, denoted as 9a in the present study), we performed large-scale molecular dynamics simulations and molecular docking operations on 5-HT1AR-9a binding. We found the flip-packing events for the headgroup of 9a, and we also found that its tail group could bind flexibly at the agornst-binding site of 5-HT1AR. By finely tuning the flip-packing phenomenon of the 9a headgroup and tuning the binding flexibility of 9a tail group, we virtually designed a series of new 9a derivatives through molecular docking operations and first-principles calculations and predicted that these newly designed 9a derivatives should be higher-affinity agonists of 5-HT1AR. The computational predictions on the new 9a derivatives have been confirmed by our wet-experimental studies as chemical synthesis, binding affinity assays, and agonistic-function assays. The consistency between our computational design and wet-experimental measurements has led to our discovery of higher-affinity agonists of 5-HT1AR, with,similar to 50-fold increase in receptor-binding affinity and similar to 25-fold improvements in agonistic function. In addition, our newly designed 5-HT1AR agonists showed very high selectivity of 5-HT1AR over subtype 5-HT2AR and also over three subtypes of dopamine receptors (D-1, D-2, and D-3).

  DOI：

  10.1021/acs.jcim.5b00164
• 作为产物：
  描述：

  环己酮 在 溶剂黄146 、 三乙胺 、 锌 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 9.0h， 生成 2-氯-N-环己烷-N-苯基乙胺
  参考文献：
  名称：

  新型吲哚烷基哌嗪衍生物作为选择性5-HT1A受体激动剂的设计，合成和结构-活性关系研究。

  摘要：

  5-HT1A受体（5-HT1AR）激动剂已涉及多种中枢神经系统（CNS）疾病的治疗，例如抑郁症和焦虑症等。基于我们先前发现的通过虚拟筛选获得的化合物FW01（Ki = 51±16 nM），通过修饰FW01的酰胺尾基和吲哚基团设计并合成了一系列FW01衍生物。SAR探索发现，酰胺尾基和吲哚基团在确定对多巴胺和5-羟色胺受体亚型的结合亲和力和选择性中起着关键作用。在所有测试的化合物中，9_24的Ki值为5±0.6 nM，对5-HT1AR的选择性很好。[35S]GTPγS分析显示9_24是对5-HT1AR的完全激动剂，EC50值为0.059 nM，显示为266.2和146。对5-HT2A和D3的选择性是4倍。用5-HT1AR-9_24进行了分子动力学模拟和分子对接研究，以揭示其高活性和选择性的机理。最后，提出了5-HT1AR的逐步9_24诱导信号转导机制。

  DOI：

  10.1021/acs.jcim.9b00926

文献信息

• [EN] COMPOUNDS OF THE FORMU;A R1-X-Y-Z-NR2R3 AS ABCA-1 ELEVATING AGENTS AGAINST CAD OR ATHEROSCLEROSIS<br/>[FR] COMPOSES DE FORMULE R1-X-Y-Z-NR2R3 UTILISES EN TANT QU'AGENTS PERMETTANT D'AUGMENTER LE NIVEAU D'EXPRESSION DU GENE ABCA-1 CONTRE LES CORONAROPATHIES (CAD) ET L'ARTHERIOSCLEROSE
  申请人：CV THERAPEUTICS INC

  公开号：WO2003103651A1

  公开（公告）日：2003-12-18

  The present invention provides compounds that elevate cellular expression of the ABCA-1 gene, promoting cholesterol efflux from cells and increasing HDL levels in the plasma of a mammal, in particular humans. The compounds are useful for treating coronary artery disease.

  本发明提供了一种能够提高细胞中ABCA-1基因表达的化合物，促进胆固醇从细胞中外流，并增加哺乳动物，特别是人类体内高密度脂蛋白水平的化合物。这些化合物对治疗冠状动脉疾病很有用。
• ABCA-1 ELEVATING COMPOUNDS
  申请人：Ibrahim N. Prabha

  公开号：US20050267215A1

  公开（公告）日：2005-12-01

  The present invention provides compounds that elevate cellular expression of the ABCA-1 gene, promoting cholesterol efflux from cells and increasing HDL levels in the plasma of a mammal, in particular humans. The compounds are useful for treating coronary artery disease.

  本发明提供了一种能够提升细胞中ABCA-1基因表达的化合物，促进胆固醇从细胞中流出，并增加哺乳动物（特别是人类）血浆中的HDL水平。这些化合物可用于治疗冠状动脉疾病。
• ABCA-1 Elevating compounds
  申请人：——

  公开号：US20020082257A1

  公开（公告）日：2002-06-27

  The present invention provides compounds that elevate cellular expression of the ABCA-1 gene, promoting cholesterol efflux from cells and increasing HDL levels in the plasma of a mammal, in particular humans. The compounds are useful for treating coronary artery disease.

  本发明提供了一种能够提高ABCA-1基因在细胞中表达的化合物，促进胆固醇从细胞中流出，并增加哺乳动物（特别是人类）血浆中的HDL水平。这些化合物可用于治疗冠状动脉疾病。
• ABCA-1 elevating compounds
  申请人：——

  公开号：US06713650B2

  公开（公告）日：2004-03-30

  The present invention provides compounds that elevate cellular expression of the ABCA-1 gene, promoting cholesterol efflux from cells and increasing HDL levels in the plasma of a mammal, in particular humans. The compounds are useful for treating coronary artery disease.

  本发明提供了一种能够提高ABCA-1基因细胞表达的化合物，从细胞中促进胆固醇外流，并增加哺乳动物（特别是人类）血浆中的高密度脂蛋白水平。这些化合物可用于治疗冠状动脉疾病。
• Design, Synthesis, and Evaluation of Indolebutylamines as a Novel Class of Selective Dopamine D3 Receptor Ligands
  作者：Peng Du、Lili Xu、Jiye Huang、Kunqian Yu、Rui Zhao、Bo Gao、Hualiang Jiang、Weili Zhao、Xuechu Zhen、Wei Fu

  DOI：10.1111/cbdd.12158

  日期：2013.9

  A series of indolebutylamine derivatives were designed, synthesized, and evaluated as a novel class of selective ligands for the dopamine 3 receptor. The most potent compound 11q binds to dopamine 3 receptor with a Ki value of 124 nm and displays excellent selectivity over the dopamine 1 receptor and dopamine 2 receptor. Investigation based on structural information indicates that site S182 located in extracellular loop 2 may account for high selectivity of compounds. Interaction models of the dopamine 3 receptor‐11q complex and structure‐activity relationships were discussed by integrating all available experimental and computational data with the eventual aim to discover potent and selective ligands to dopamine 3 receptor.